Our latest articles
How long can it be before the total breaches $10bn?
Three of the top five buyouts of 2021 happened in the final quarter, and with biotech stocks hurting many hope that the flurry will continue.
With pivotal sepofarsen data due, the group will hope to get one up on Editas.
An analyst call over the Aduhelm coverage debacle sees Biogen threaten more cost cutting.
2021 was a huge year for IPOs, with pure-play developers raising $14bn, but 2022 is likely to tell a different story.
Phase 2 data could indicate whether the big pharma has a chance of disrupting Vertex’s monopoly.
The US Centers for Medicare & Medicaid Services’ national coverage determination for Biogen’s Aduhelm makes for uncomfortable reading.
Lilly pips Pfizer to the big pharma top spot on share price performance, while Covid-19 drives the largest risers elsewhere.
But unimpressive phase 2 results, plus a lack of a placebo control arm, raise questions.
Insulin pumps and glucose sensors flew off the shelves, whereas liquid biopsy developers both soared and sank.